For those who care for someone with Parkinson's disease
[Home] [Forum] [Help] [Search] [Register] [Login] [Donate]
You are not logged in


Topic pepcid Go to previous topic Go to next topic Go to higher level

By lurkingforacure On 2010.03.31 07:06
Read this and thought it might help some others, we will be trying it as soon as we get back onto our Mirapex regime after the disastrous attempt to switch to requip...38% more on-time is HUGE, that's like another whole dose of med (for us):

2010 Mar 22. [Epub ahead of print]
Effect of histamine H(2) receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Johnston TH, van der Meij A, Brotchie JM, Fox SH.
Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

Levodopa-induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these problems. Here, we asses the ability of the clinically available, selective histamine H(2) antagonist, famotidine (1, 3, and 30 mg/kg) to treat levodopa-induced dyskinesia and wearing off in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-macaque model of PD. Famotidine (3 mg/kg) increased peak activity, enhanced peak anti-parkinsonian action (1 and 3 mg/kg), and extended duration of action (3 mg/kg, by 38%) of a low dose of levodopa (compared to low dose levodopa alone). Enhancement of anti-parkinsonian actions of low dose levodopa by famotidine (3 mg/kg) was associated with only mild, nondisabling dystonia. Famotidine had no effect on the anti-parkinsonian actions of high dose levodopa (compared to high dose levodopa alone). However, famotidine (1, 3, and 30 mg/kg) had a significant effect on chorea, but not dystonia, induced by high dose levodopa (compared to high dose levodopa alone). Famotidine increased high dose levodopa-induced "good quality" on time, i.e., on time not associated with disabling dyskinesia, by up to 28% (compared to high dose levodopa alone). In conclusion, famotidine, a drug currently available for use in the clinic, can enhance the peak-dose anti-parkinsonian actions and extend total duration of action of a low dose of levodopa, without producing disabling dyskinesia. Furthermore, in combination with a higher dose of levodopa, famotidine can reduce peak-dose levodopa-induced chorea and improve the quality of on-time.

PMID: 20310030 [PubMed - as supplied by publisher]

By packerman On 2010.03.31 09:40
when i looked this up, i found that some side effects are constipation and dizziness...which most of us are fighting already...although this does sound hopeful and we will probably try it too.


© MyParkinsons.org · Published by jAess Media · Privacy Policy & Terms of Use
Sponsorship Assistance for this website and Forum has been provided by by people like you